Skip to main content

Advertisement

Table 1 Clinicopathologic features of the neoadjuvant chemotherapy plus radiotherapy (NACT + RT) group and the concurrent chemoradiotherapy (CCRT) group of patients with ascending-type nasopharyngeal carcinoma (NPC)

From: Radiotherapy with neoadjuvant chemotherapy versus concurrent chemoradiotherapy for ascending-type nasopharyngeal carcinoma: a retrospective comparison of toxicity and prognosis

Variable NACT + RT group CCRT group P value
Total 98 116  
Age (years) 0.367
 Median 44 45  
 Range 17–70 16–70  
Gender [cases (%)] 0.179
 Male 84 (85.7) 90 (77.6)  
 Female 14 (14.3) 26 (22.4)  
Histology [cases (%)] 0.795
 WHO II 5 (5.1) 8 (6.9)  
 WHO III 93 (94.9) 108 (93.1)  
T stage [cases (%)]a 0.131
 T3 43 (43.9) 64 (55.2)  
 T4 55 (56.1) 52 (44.8)  
N stage [cases (%)]a 0.118
 N0 34 (34.7) 47 (40.5)  
 N1 64 (65.3) 69 (59.5)  
Total radiation dose (Gy) 0.721
 Median 70 69  
 Range 66–72 66–72  
Overall duration of radiotherapy (days) 0.674
 Median 46 47  
 Range 40–49 42–51  
  1. WHO World Health Organization
  2. aAccording to the Union for International Cancer Control/American Joint Committee on Cancer staging system, 7th edition